AKEBIA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.365 USD | +0.37% |
|
-2.86% | +9.68% |
| 01:41pm | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
| Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
Financials (USD)
| Sales 2024 * | 189M | Sales 2025 * | 171M | Capitalization | 285M |
|---|---|---|---|---|---|
| Net income 2024 * | -63M | Net income 2025 * | -63M | EV / Sales 2024 * | 1.51 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.66 x |
| P/E ratio 2024 * |
-4.69
x | P/E ratio 2025 * |
-4.74
x | Employees | 167 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Akebia Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 week | -2.16% | ||
| Current month | -25.68% | ||
| 1 month | -37.33% | ||
| 3 months | -2.16% | ||
| 6 months | +63.88% | ||
| Current year | +9.68% |
1 week
1.31
1.44
1 month
1.312.48
Current year
1.212.48
1 year
0.652.48
3 years
0.244.33
5 years
0.2413.71
10 years
0.2431.00
| Managers | Title | Age | Since |
|---|---|---|---|
John Butler
CEO | Chief Executive Officer | 59 | 13-06-30 |
Tracey Vetterick
ADM | Chief Administrative Officer | - | 22-03-31 |
Michel Dahan
COO | Chief Operating Officer | 45 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Rogers
BRD | Director/Board Member | 64 | 18-12-11 |
Adrian Adams
CHM | Chairman | 73 | 18-12-11 |
| Director/Board Member | 65 | 21-02-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 1.35 | -0.74% | 1 733 171 |
| 24-04-22 | 1.36 | 0.00% | 2,006,106 |
| 24-04-19 | 1.36 | -2.16% | 2,956,394 |
| 24-04-18 | 1.39 | 0.00% | 2,562,577 |
| 24-04-17 | 1.39 | -0.71% | 2,944,347 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotes
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Companyâs portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.36
USD
Average target price
5
USD
Spread / Average Target
+267.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.68% | 285M | |
| -1.71% | 103B | |
| +2.49% | 96.73B | |
| -0.03% | 21.31B | |
| -16.61% | 21.21B | |
| -6.45% | 18.79B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B |
- Stock Market
- Equities
- AKBA Stock
